Efficacy and Safety of Cinacalcet in the Treatment of Hemodialysis Patients with Secondary Hyperparathy-roidism:A Systematic Review / 中国药房
China Pharmacy
;
(12): 2937-2940,2941, 2016.
Article
in Chinese
| WPRIM
| ID: wpr-605743
ABSTRACT
OBJECTIVE:
To systematically review the efficacy and safety of cinacalcet in the treatment of hemodialysis pa-tients with secondary hyperparathyroidism,and provide evidence-based reference for the clinical treatment.METHODS:
Retrieved from Medline,Cochrane Library,EMBase and CBM,randomized controlled trials(RCT)about cinacalcet in the treatment of he-modialysis patients with secondary hyperparathyroidism (SHPT) were collected. Meta-analysis was performed by using Rev Man 5.3.5 software after data extract and quality evaluation by Cochrane systematic Rev Man 5.3.5.RESULTS:
Totally 7 RCTs were en-rolled,involving 1 987 patients. Results of Meta-analysis showed cinacalcet can significantly reduce the rate of surgical parathyroid-ectomy[RR=0.23,95%CI(0.06,0.89),P=0.03],incidence of fracture[RR=0.26,95%CI(0.12,0.60),P=0.002] and increase the incidences of hypocalcemia[RR=9.81,95%CI(3.92,4.59),P<0.001],nausea[RR=1.97,95%CI(1.58,2.46),P<0.001] and vomit-ing[RR=1.91,95%CI(1.50,2.42),P<0.001],while it showed no significant effect on the the incidence of all-cause mortality and cardiovascular death.CONCLUSIONS:
The clinical efficacy of cinacalcet in the treatment of hemodialysis patients with secondary hyperparathyroidism is good,but there are common adverse reactions such as nausea and vomiting,hypocalcemia.
Full text:
Available
Index:
WPRIM (Western Pacific)
Type of study:
Controlled clinical trial
/
Systematic reviews
Language:
Chinese
Journal:
China Pharmacy
Year:
2016
Type:
Article
Similar
MEDLINE
...
LILACS
LIS